Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
Effect of Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors: a Randomized Placebo-controlled Trial
Beijing Tiantan Hospital
366 participants
Jan 25, 2024
INTERVENTIONAL
Conditions
Summary
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium
Eligibility
Inclusion Criteria3
- Patients with temporal glioma scheduled for a elective craniotomy
- Age ≥18 years
- Obtain written informed consent.
Exclusion Criteria9
- Patients with severe preoperative cognitive impairment
- History of traumatic brain injury or previous neurosurgery
- History of psychotropic medications
- Allergy to dexmedetomidine
- Pregnant or lactating women
- History of obstructive sleep apnoea syndrome
- Severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block
- Severe hepatic dysfunction
- Severe renal dysfunction
Interventions
In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06164314